Baxter International Inc. (BAX)

Baxter International's stock experienced a challenging period over the past six months, decreasing by 7.65% and approximately 30.64% over the past year. On October 30, 2025, the stock fell 14.5% due to a revenue miss, reduced full-year adjusted EPS guidance, and a cut in expected sales growth, impacted by hurricane-related disruptions and weakness in its infusion pump portfolio. Analyst ratings and price targets saw adjustments, including Barclays cutting the price target to $30, Wall Street Zen downgrading to "hold", Morgan Stanley decreasing the target price to $15.00, and Zacks Research lowering the rating to "strong sell". Citigroup also reduced its price objective to $21.00. The company also recently cut its dividend to $0.01 quarterly.

Information regarding demand seasonality for Baxter International's products and services presents a mixed picture. The company has shown a year-over-year revenue increase of 5.0%, suggesting a positive trend in sales and market demand. Baxter demonstrated positive sales growth in its Healthcare Systems & Technologies segment in the first two quarters of 2025. However, the third quarter of 2025 highlighted "weak U.S. demand" and "stagnant core product sales." Foreign exchange rates have also acted as a headwind for Baxter's revenue growth. The aging baby boomer generation is expected to lead to increased demand for healthcare, which in turn could increase demand for Baxter's products in the long term.

Baxter International, Inc. is a multinational healthcare company specializing in medical products, pharmaceuticals, and healthcare technologies. The company focuses on developing and manufacturing products to treat chronic and acute medical conditions, operating across three main business segments: Medical Product and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Product and Therapies segment includes Advanced Surgery and Infusion Therapies and Technologies, encompassing sterile IV solutions, infusion systems, parenteral nutrition therapies, and surgical products. The Healthcare Systems and Technologies segment includes Front Line Care, Digital Platform and Innovations, Care and Connectivity Solutions, and Global Services, expanded by the acquisition of Hillrom to include hospital beds and patient monitoring tools. The Pharmaceuticals segment produces inhalational anesthetics and other hospital pharmaceuticals. In 2023, Baxter's global net sales reached $14.8 billion, a 2% increase from 2022.

Baxter International has a significant global presence, with products and digital health solutions available in over 100 countries. The company operates across the Americas, EMEA, and APAC regions, with specific subsidiary and operational locations in countries like Australia, Belgium, Brazil, Canada, China, and the United States.

Baxter International's brand reputation was impacted by issues surrounding its Novum LVP infusion pump. In December 2025, a class action securities lawsuit was filed against Baxter, alleging the company misled the market about safety issues and the performance of the Novum LVP between February 2022 and October 2025. The complaint claims that the Novum LVP suffered systemic defects causing malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, leading to risks of serious injury or death for patients. On July 31, 2025, Baxter announced a voluntary and temporary pause on shipments and installations of the Novum LVP, leading to a significant drop in the company's stock price. The FDA classified these issues as a Class I recall, indicating a risk of severe injury or death.

Institutional investors hold a substantial portion of Baxter International's stock, with 1236 institutional owners holding 623,889,985 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Dodge & Cox, Pzena Investment Management Llc, State Street Corp, Fmr Llc, and Price T Rowe Associates Inc /md/, collectively owning over 90% of the company's stock. Insider ownership constitutes 6.45% of the company's equity base, totaling approximately 33.10 million shares. Key insider holders include Chairman and CEO Andrew Hider, former Chairman and CEO Jose E Almeida, EVP and CFO Joel T. Grade, and EVP and Chief HR Officer Jeanne K Mason.